Emmaus Life Sciences, Inc. (EMMA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.03
- As of
Kresmion compiles this page from EMMA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Emmaus Life Sciences, Inc. (EMMA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-14.
See the full EMMA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EMMA on one page. Preview it with sample data, then open it live with a free account.
Preview the EMMA dossierActive events for EMMA
- lowEarnings below estimates
Q1-2022: EPS $-0.03 vs $0.0102 estimate, -0.04 on a near-zero consensus
- lowEarnings below estimates
Q2-2022: EPS $-0.18 vs $0.0102 estimate, -0.19 on a near-zero consensus
- lowEarnings below estimates
Q3-2022: EPS $-0.03 vs $0.0102 estimate, -0.04 on a near-zero consensus
- lowEarnings below estimates
Q3-2022: EPS $-0.18 vs $0.0102 estimate, -0.19 on a near-zero consensus
- lowEarnings below estimates
Q3-2022: EPS $-0.01 vs $0.0102 estimate, -0.02 on a near-zero consensus
FREE, NO ACCOUNT
Every event on EMMA, as it fires
New filings, 13F moves and cross asset events on EMMA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, EMMA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
EMMA's 10-Q filed Aug 14, 2026 states:
…there is substantial doubt about the Company's ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on EMMA
EMMA against its peers
EMMA's operating margin of 1.9% ranks in the 95th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | EMMA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 12.5M USD | 1.9M USD | 72 | 8 |
| Gross margin | 93.1% | n/a | n/a | 4 |
| Operating margin | 1.9% | -869.3% | 95 | 9 |
| Net margin | -60.2% | -862.3% | 85 | 9 |
| Return on equity | n/a | -200.6% | n/a | 13 |
Peers (19): GNPX, PPCB, KPTI, KAPA, GOVX, OGEN, BRTX, PPBT, ATXI, SLXN, CASIF, AGTX, HCWB, REVB, BDRX, ACUT, APVO, VIVS, ISCO. Left out: XRTX (no annual filing), ENLV (no annual filing), ELAB (no annual filing), CLSDQ.D (no annual filing), AGNPF (no annual filing), GPLL (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (EMMA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in EMMA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on EMMA in the last 180 days.
Upstream: SEC EDGAR filings for EMMA
Kresmion, "Emmaus Life Sciences, Inc. (EMMA) institutional holdings and SEC filings", data as of 2026-08-14, https://kresmion.com/research/EMMA. Upstream data: SEC EDGAR filings for EMMA.
Link to this data (HTML):
<a href="https://kresmion.com/research/EMMA">Emmaus Life Sciences, Inc. (EMMA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow EMMA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to EMMA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.